SecBot SecBot

MESO

MESOBLAST LTD
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. C3· CIK 0001345099 Biotech & Drug Discovery
$12.45 −0.82 (−6.18%)
Nov 16 4:00 PM ET · prev $13.27
Market cap
$1.7B
Small cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
🔒 Subscribers only
1 year
−17.5%
from $15.09 · Nov 17
30 days
+4.2%
from $11.95
52-week range
$11.95–20.96
−41% from high · low Oct 19
Avg volume 20D
254.6K
Oct 29 spike 696.5K
Short interest
3.58M
≈2.8% of shares · +9.5%
Days to cover
10.2
at average volume
Insider net
+$30.0M
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
19
analyzed by SecBot
SecBot read BULLISH 12 reports · 90 days
Balance 0 bearish · 5 bullish · 1 mixed · 6 neutral oldest → newest, height = score
Avg score ·High conf. 11/12

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $30.0M. No open-market sales.

  • InstitutionsBULLISH

    Q3 2026: 8 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.080 → −$0.080 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +9.5% to 3.58M shares. 10.2 days to cover, ≈2.8% of shares.

  • TrendRANGE

    12% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
GROUP ONE TRADING LLCDOUBLED132,239$1.9M
BNP PARIBAS FINANCIAL MARKETSDOUBLED30,177$442.1K
BARCLAYS PLCADD4,863$71.2K
OSAIC HOLDINGS, INC.ADD2,776$41.0K
JONES FINANCIAL COMPANIES LLLPDOUBLED800$12.1K
Allworth Financial LPDOUBLED251$3.4K
NISA INVESTMENT ADVISORS, LLCDOUBLED54$791.00
MORGAN STANLEYADD718,608$9.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy2Buy7Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 27, 2026Piper Sandler
REITERATE
REITERATEOverweight

Insider ledger

Form 4
$30.0M
bought · 1 insider
$0
sold · 0 insiders
DateInsiderTypeValue
Apr 10, 2026
George Gregory
Director
Apr 10, 2026
BUY$3.4M
Apr 10, 2026
George Gregory
Director
Apr 10, 2026
BUY$3.4M
Apr 9, 2026
George Gregory
Director
Apr 9, 2026
BUY$7.2K
Apr 9, 2026
George Gregory
Director
Apr 9, 2026
BUY$14.1K
Apr 9, 2026
George Gregory
Director
Apr 9, 2026
BUY$7.5K
Apr 9, 2026
George Gregory
Director
Apr 9, 2026
BUY$14.3K
Apr 9, 2026
George Gregory
Director
Apr 9, 2026
BUY$28.6K
Apr 9, 2026
George Gregory
Director
Apr 9, 2026
BUY$6.9K

Earnings setup

Estimates
−$0.08
EPS estimate, this quarter
−200%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.08-$0.08–-$0.08-200.0%$54.9M
Next Q-$0.07-$0.07–-$0.07-187.5%$57.2M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
3,577,405
shares short
+9.5%
vs prior settlement
10.2
days to cover
≈2.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent
Nov 15, 2026
Press release
Mesoblast Showcased at ASX Premier Investor Day Event
NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for…
Nov 4, 2026
Press release
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for…
Nov 1, 2026
Press release
Mesoblast Board Changes
NEW YORK, Nov. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for…
Oct 30, 2026
Short interest
Short Interest: MESO up 9% to 3.6M shares
Settlement 2026-10-30 | Days to cover: 10.16 | ≈2.75% of shares outstanding (est.)
Oct 28, 2026
Earnings
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for…

SecBot reports

19 filings · 6 press releases · 11 bullish · 0 bearish · 2 mixed · 6 neutral
All MESO filing & press-release reports (25)